Mattia Galli/LinkedIn
Nov 2, 2025, 05:36
Mattia Galli on Use of Genetic Testing to Guide the Choice of Antiplatelet Drugs
Mattia Galli, Assistant Professor at Sapienza University of Rome, Associate Editor of European Heart Journal, shared on LinkedIn:
”Growing interest in Rome in the use of genetic testing to guide the choice of antiplatelet drugs.
Is the time finally ripe for cardiology to move towards precision drug therapy?
A wonderful meeting and stimulating discussion with colleagues from one of Rome’s most important hospitals, in a session moderated by some of the “teachers” I had the pleasure of meeting during my specialization course.
Francesco Burzotta, Gaetano Antonio Lanza.”

Stay updated with Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support